New! Fundraise with Daffy Campaigns 🚀

Global Alliance For Tb Drug Development Inc.

Global Alliance For Tb Drug Development Inc.

New York, NY 10005
Tax ID13-4128413

Want to make a donation using Daffy?

Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.

Payment method

Frequency

Amount

$USD
Daffy covers all ACH transaction fees so 100% of your donation goes to your favorite charities.

Do you work for Global Alliance For Tb Drug Development Inc.? Learn more here.

About this organization

Revenue

$63,283,490

Expenses

$60,315,645

Website

tballiance.org

Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

About

RESEARCH AND DEVELOPMENT - TB Alliance is a not-for-profit product development partnership (PDP), uniquely positioned to leverage a global network of public and private partners to most efficiently advance TB drug development. A PDP builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. PDPs retain direct management oversight of their projects, though much of the laboratory and clinical work is done though external research facilities and contractors. We combine the research and development expertise of our staff with the skills and resources of our partners to harness the most promising science wherever it may exist around the world. This model minimizes costs, including overhead and investments in infrastructure, while optimizing scientific capability to speed new TB drug development. Our business model and diverse partnerships allow TB Alliance to leverage additional partner services for every dollar invested in the TB Alliance. NIX-TB - The phase 3 Nix-TB trial is an open-label, single arm trial that is evaluating the BPaL regimen. Nix-TB participants with extensively drug-resistant tuberculosis (XDR-TB) and treatment-intolerant or non responsive multidrug-resistant (MDR) TB were treated with bedaquiline, pretomanid and linezolid over six months, extended to nine months in two cases, with the intent to cure. Nix-TB enrolled 109 participants in three sites in South Africa. OPTIMIZED FIRST-LINE DRUGS IN CHILDREN >5KG - TB Alliance is working to develop appropriate child-friendly formulations of the current standard TB treatment. The first wave of these new products has already reached market. SIMPLICITB - SimpliciTB is evaluating the efficacy, safety and tolerability of a novel and potentially shorter drug regimen (BPaMZ) for patients with drug-sensitive (DS) and drug-resistant (MDR) pulmonary tuberculosis (specifically multidrug-resistant TB and mono-resistance to isoniazid and rifampicin). The BPaMZ regimen is comprised of four different antimicrobials: Bedaquiline (B), Pretomanid (Pa), Moxifloxacin (M) and Pyrazinamide (Z). The new drug regimen will be administered for four months to patients with DS-TB, and for six months to patients with MDR-TB or mono-resistance to rifampicin or isoniazid. Results in the DS-TB arm will be compared to a control group of the standard six-month drug regimen for DS-TB (HRZE). ZENIX - The phase 3 ZeNix clinical trial is evaluating the BPaL regimen to treat extensively drug resistant tuberculosis (XDR-TB) and those with pre-XDR-TB and multi-drug resident TB (MDR-TB) whose prior treatment has failed or who have not tolerated their treatment. It seeks to optimize linezolid dosing as part of the BPaL regimen, evaluating both the linezolid dose and the linezolid duration.

Interesting data from their 2019 990 filing

The filing clearly states the mission of the non-profit as “Tb alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.”.

When outlining its functions, they were explained as: “To accelerate the discovery & development of new drugs to facilitate the control of tuberculosis throughout the world and the accessibility of these drugs to the global community.”.

  • In compliance with legal regulations, the non-profit has reported their state of operation as DE.
  • The filing records the non-profit's address for 2019 as 40 WALL STREET 24TH FLOOR, NEW YORK, NY, 10005.
  • As of 2019, the non-profit's form reports a total of 53 employees.
  • Does not operate a hospital.
  • Does not operate a school.
  • Does not collect art.
  • Does not provide credit counseling.
  • Has foreign activities.
  • Is not a donor advised fund.
  • Is not a private foundation.
  • Expenses are greater than $1,000,000.
  • Revenue is greater than $1,000,000.
  • Revenue less expenses is $2,967,845.
  • The CEO's salary plan within the organization is subject to review and endorsement by an independent body.
  • The organization has a written policy that describes how long it will retain documents.
  • The organization has a foreign financial account.
  • The organization has 9 independent voting members.
  • The organization was formed in 2000.
  • The organization has a written policy that addresses conflicts of interest.
  • The organization is required to file Schedule B.
  • The organization is required to file Schedule J.
  • The organization is required to file Schedule O.
  • The organization pays $13,493,212 in salary, compensation, and benefits to its employees.
  • The organization pays $991,904 in fundraising expenses.
  • The organization provides Form 990 to its governing body.
  • The organization has minutes of its meetings.
  • The organization has a written whistleblower policy.
  • The organization's financial statements were reviewed by an accountant.

Additional Non-Profits in the area

By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.